News

US FDA approves Moderna’s Covid-19 vaccine, Spikevax in children aged 6 months through 11 years at increased risk for Covid-19 disease: Cambridge, Massachusetts Saturday, July 1 ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
In the latest close session, Moderna (MRNA) was down 1.87% at $33.64. This move lagged the S&P 500's daily loss of 0.33%. Meanwhile, the Dow lost 0.63%, and the Nasdaq, a tech-heavy index, lost 0.22%.
The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...
What Happened? A number of stocks fell in the morning session after the U.S. administration announced a sharp escalation in ...